Soligenix to present data on two bio-defense drug programs

Soligenix said on Monday that it would present pre-clinical data from two bio-defense programs at the American Society of Microbiology (ASM) Biodefense and Emerging Diseases Research meeting Feb. 9-11.

The two presentations will cover the efficiency findings of the company's SGX943, a potential treatment for melioidosis, and RiVax, a potential antitoxin and vaccine against ricin that can been inhaled in a gaseous form.

The potential melioidoisis treatment utilizes innate defense regulators in the immune system to stem inflammation from the condition. Because it does not directly interact with the infectious agent, concerns about bacterial resistance developing are minimal. This presentation will take place at the Washington Marriott Wardman Park in Washington, D.C., on Feb. 10 beginning at 5:45 p.m. EST. Soligenix Chief Scientific Officer Dr. Oreola Donini will be presenting the data.

RiVax utilizes an antigen present in ricin that does not cause any of ricin's toxic side affects, the company said, and when paired with Soligenix's ThermoVax, Rivax's temperature is kept stable, which prolongs its shelf life. This presentation, also by Donini, will take place Feb. 11 at 3:45 p.m. EST at the Marriott Wardman Park.

Both programs are funded with support from the National Institute of Allergy and Infectious Diseases.